Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H115

UPID:
SNAB_HUMAN

ALTERNATIVE NAMES:
N-ethylmaleimide-sensitive factor attachment protein beta

ALTERNATIVE UPACC:
Q9H115; B4DK44; Q4G0M0; Q4G187; Q5JXF9; Q8N3C4

BACKGROUND:
Essential for cellular transport, the Beta-soluble NSF attachment protein, alternatively known as N-ethylmaleimide-sensitive factor attachment protein beta, facilitates the movement of molecules between the endoplasmic reticulum and the Golgi apparatus. Its function is pivotal in maintaining cellular homeostasis and protein processing.

THERAPEUTIC SIGNIFICANCE:
Linked to the autosomal recessive form of Developmental and epileptic encephalopathy 107 (DEE107), the Beta-soluble NSF attachment protein's dysfunction manifests in severe global developmental delay, profound intellectual disability, and refractory seizures. Targeting the underlying genetic variants affecting this protein could unveil groundbreaking treatments for DEE107, significantly improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.